FSA
ABBV icon

Fort Sheridan Advisors’s AbbVie ABBV Stock Holding History

Fort Sheridan Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.8M Buy
68,168
+3,077
+5% +$683K 1.79% 11
2025
Q4 		$14.9M Buy
65,091
+211
+0.3% +$48.1K 1.89% 12
2025
Q3 		$15M Sell
64,880
-735
-1% -$150K 1.97% 12
2025
Q2 		$12.2M Sell
65,615
-864
-1% -$161K 1.74% 12
2025
Q1 		$13.9M Sell
66,479
-11
-0% -$2.14K 2.11% 11
2024
Q4 		$11.8M Buy
66,490
+1,307
+2% +$240K 1.72% 11
2024
Q3 		$12.9M Buy
65,183
+1,511
+2% +$282K 1.95% 11
2024
Q2 		$10.9M Buy
63,672
+18,289
+40% +$3.03M 1.76% 12
2024
Q1 		$8.26M Buy
45,383
+401
+0.9% +$69.1K 1.56% 13
2023
Q4 		$6.97M Buy
44,982
+2,319
+5% +$338K 1.39% 14
2023
Q3 		$6.36M Buy
42,663
+2,207
+5% +$324K 1.44% 14
2023
Q2 		$5.45M Buy
40,456
+2,591
+7% +$380K 1.24% 16
2023
Q1 		$6.03M Buy
37,865
+17,410
+85% +$2.66M 1.53% 14
2022
Q4 		$3.31M Sell
20,455
-552
-3% -$84.6K 1.08% 21
2022
Q3 		$2.82M Buy
21,007
+516
+3% +$74K 0.95% 22
2022
Q2 		$3.14M Sell
20,491
-75
-0.4% -$11.5K 1.02% 22
2022
Q1 		$3.33M Sell
20,566
-1,313
-6% -$191K 0.98% 21
2021
Q4 		$2.96M Buy
21,879
+247
+1% +$29.2K 0.85% 22
2021
Q3 		$2.33M Buy
21,632
+1,810
+9% +$207K 0.76% 29
2021
Q2 		$2.23M Buy
19,822
+1,330
+7% +$150K 0.74% 30
2021
Q1 		$2M Buy
18,492
+5,306
+40% +$568K 0.79% 26
2020
Q4 		$1.41M Buy
13,186
+1,743
+15% +$167K 0.69% 29
2020
Q3 		$1M Buy
11,443
+33
+0.3% +$3.11K 0.59% 30
2020
Q2 		$1.12M Buy
11,410
+118
+1% +$10.4K 0.69% 26
2020
Q1 		$860K Buy
11,292
+605
+6% +$51.5K 0.63% 30
2019
Q4 		$946K Buy
10,687
+3,682
+53% +$306K 0.51% 34
2019
Q3 		$530K Buy
7,005
+2,402
+52% +$165K 0.3% 45
2019
Q2 		$335K Buy
+4,603
New +$362K 0.19% 64

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fort Sheridan Advisors's ABBV Position: Q1 2026 in Review

Fort Sheridan Advisors increased its AbbVie (ABBV) stake by 4.7% in Q1 2026, buying an estimated $683K and bringing the position to 68,168 shares worth $14.8M. The position accounts for 1.79% of the portfolio, ranked #11.

Fort Sheridan Advisors first reported a position in ABBV in Q2 2019 and has held it in 28 quarters since. The position peaked at $15M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Fort Sheridan Advisors held 68,168 shares of AbbVie worth $14.8M as of Q1 2026.
  • Fort Sheridan Advisors bought 3,077 AbbVie shares in Q1 2026, an estimated $683K.
  • AbbVie made up 1.79% of Fort Sheridan Advisors's portfolio in Q1 2026, its #11 holding.
  • Fort Sheridan Advisors first reported a position in AbbVie in Q2 2019 and has held it in 28 quarters since.
  • Fort Sheridan Advisors's AbbVie position peaked at $15M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fort Sheridan Advisors's 13F filing for Q1 2026, filed 6 May 2026.